TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results

TESARO (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today reported operating results for fourth-quarter and full-year 2017, and provided an update on the Company’s commercial products and development programs.

As quoted in the press release:

“Following its April 2017 introduction in the U.S., ZEJULA quickly became the market-leading PARP inhibitor for women with ovarian cancer, and in the second half of 2017, six out of ten ovarian cancer patients who were treated with a PARP inhibitor received ZEJULA,” said Lonnie Moulder, CEO of TESARO. “Additionally, we are expanding the ZEJULA franchise with our ongoing launches in Europe and a focused clinical development program that utilizes both monotherapy and combination approaches to potentially further lengthen the time women with ovarian cancer are free from disease progression. 2018 will be an exciting year for our immuno-oncology portfolio as we anticipate multiple data readouts, including response data for TSR-042, our anti-PD-1 antibody, in patients with lung cancer and MSI-high tumors, initial results from the combination of TSR-022, our anti-TIM-3 antibody and TSR-042, and initial data from TSR-033, our anti-LAG-3 antibody.”

Click here to read the full press release.